Respiratory tract diseases research hub
4 indexed studies · 3 currently recruiting
- recruitingTherapeutic exploratory (Phase II)
A randomized, double blind, placebo controlled, Proof of Concept (PoC) study to assess the efficacy, safety and tolerability of itepekimab in participants with inadequately controlled chronic rhinosinusitis without nasal polyps
This clinical trial is testing a new medicine called itepekimab for adults with ongoing sinus swelling that has not cleared up with standard treatments. Researchers want to find out if the medicine can safely reduce inflammation inside the sinuses, clear blockages seen on CT scans, and relieve everyday nasal symptoms.
Portugal · Poland · Italy - recruitingTherapeutic exploratory (Phase II)
A randomized Phase 2, double-blind, placebo-controlled, parallel-group, 2-arm study to assess the efficacy, safety, and tolerability of subcutaneous lunsekimig in adult participants with chronic rhinosinusitis with nasal polyps (CRSwNP)
This study looks at a new medicine called lunsekimig for adults with long-term stuffy nose and growths called nasal polyps. It compares lunsekimig to a dummy medicine to see if it makes symptoms better and if it's safe.
Bulgaria · Poland · Belgium - recruitingPHASE4
Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism
This study looks at the best way to treat small blood clots in the lungs (isolated subsegmental pulmonary embolism) in people at low risk. It compares watching carefully without treatment to giving blood-thinning medicine to reduce bleeding risks.
Belgium · Canada · France - authorisedHuman Pharmacology (Phase I)- First administration to humans
Adoptive TIL therapy in combination with chemoimmunotherapy in advanced NSCLC patients
This early-stage study is looking at a new way to treat lung cancer called adoptive TIL therapy. It combines this new treatment with standard chemotherapy and immunotherapy. The goal is to see if it's safe and how it works in adults with advanced non-small cell lung cancer.
Netherlands